Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …

Integrins mediate cell adhesion and transmit mechanical and chemical signals to the cell
interior. Various mechanisms deregulate integrin signaling in cancer, empowering tumor …

Ongoing research has revealed that the existence of cancer stem cells (CSCs) is one of the
biggest obstacles in the current cancer therapy. CSCs make an influential function in tumor …

Glioblastoma is an aggressive and heterogeneous tumor in which glioblastoma stem cells
(GSCs) are at the apex of an entropic hierarchy and impart devastating therapy resistance …

The brain tumor microenvironment (TME) is emerging as a critical regulator of cancer
progression in primary and metastatic brain malignancies. The unique properties of this …

Glioblastoma (GBM) is the most aggressive and deadliest of the primary brain tumors,
characterized by malignant growth, invasion into the brain parenchyma, and resistance to …

Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

Glioblastoma is a devastating form of brain cancer. To identify aspects of tumor
heterogeneity that may illuminate drivers of tumor invasion, we created a glioblastoma tumor …

Glioma stem cells (GSCs) are thought to underlie glioma initiation, evolution, and resistance
to existing therapies. Although functional evidence for GSCs is abundant, tumor …

Cancer stem cells (CSCs), also known as tumor‐initiating cells (TICs), are elucidated as
cells that can perpetuate themselves via autorestoration. These cells are highly resistant to …